Earnings Call Transcripts

Johnson & Johnson Q3 2025 Earnings Call - Momentum: New launches and a MedTech reshuffle offset Stelara loss of exclusivity

Johnson & Johnson reported a strong Q3 2025, with $24 billion in sales and 5.4% operational growth, driven by an aggressive new-product cadence across oncology, immunology, neuroscience, cardiovascula...

• Q3 topline: $24.0 billion in sales, 5.4% operational growth despite an approximate 640-basis-point headwind from Stelara loss of exclusivity.
• Innovative Medicine: $15.6 billion, up 5.3% operationally, with a cited ~1,070-basis-point Stelara headwind in that segment yet still showing robust in-market momentum.
• MedTech: $8.4 billion, up 5.6% operationally, with strength in cardiovascular, electrophysiology, vision and shockwave technologies.
• +12 more takeaways

Senseonics Second Quarter 2025 Earnings Call - Eversense 365 Launch Accelerates, $77.8M Raised to Fund DTC Push and Pipeline

Senseonics reported clear commercial momentum for Eversense 365, with new patient starts rising 79% year over year and 37% sequentially, and leads more than doubling versus last year. Management raise...

• New patient momentum: Eversense 365 new patient starts rose 79% year over year and 37% sequentially in Q2, with leads more than doubling versus prior year and June leads 50% above the prior three month average.
• Financing bolsters runway: Senseonics raised approximately $77.8 million in gross proceeds in Q2, including a $20 million concurrent placement with Abbott, leaving cash, restricted cash and equivalents of about $126.7 million as of June 30, 2025.
• Planned DTC acceleration: Company will more than double previously planned direct to consumer spend with Ascensia, committing over $10 million across the next two quarters to boost leads and conversions.
• +12 more takeaways

CareDx Q2 2025 Earnings Call - Volume and profitability rebound met by looming Medicare LCD risk

CareDx reported a clear operational rebound in Q2 2025: adjusted revenue of $90.5M, testing volume of ~49,500 results (up 13% YoY), and adjusted EBITDA of $9.1M versus a loss in the year-ago quarter. ...

• Adjusted revenue (ex. prior-period tests) was $90.5M in Q2 2025, up 14% year over year; reported revenue was $86.7M after a $3.8M prior-period test write-off.
• Adjusted EBITDA improved to $9.1M in Q2 2025, vs an adjusted loss of $0.3M in Q2 2024, driven by volume growth and operating leverage.
• Testing services delivered ~49,500 test results in the quarter, up 13% YoY, marking the eighth consecutive quarter of sequential testing volume growth.
• +13 more takeaways

Universal Technical Institute Third Quarter 2025 Earnings Call - Concord Growth Restrictions Lifted, Raises 2025 Guidance

Universal Technical Institute turned in a tidy quarter, with revenue up 15% and adjusted EBITDA up 37% as demand for skilled trades and allied health programs remained strong. Management used the call...

• Revenue rose 15.1% year over year to $204.3 million in Q3 2025, beating expectations and showing sustained top line momentum.
• Adjusted EBITDA increased 37.3% year over year to $25.3 million, a big operational beat, though comparisons are complicated by accounting and investment timing changes.
• Net income was $10.7 million, up roughly 114% year over year, with diluted EPS of $0.19 for the quarter.
• +15 more takeaways

Koru Medical Systems Q2 2025 Earnings Call - Revenue Tops $10.2M, International Prefill Conversions Lift Guide

Koru reported a clean quarter of operational momentum, posting record Q2 revenue of $10.2 million, up 21% year over year, and raised full-year revenue guidance to $39.5 million to $40.5 million. Growt...

• Record Q2 revenue of $10.2 million, up 21% year over year.
• Raised 2025 revenue guidance to $39.5 million to $40.5 million, a $1.0 million increase tied primarily to international prefilled syringe conversions.
• Domestic core revenue was $7.1 million, up 15% year over year, driven by recurring SCIG patient growth and market share gains.
• +17 more takeaways

electroCore Q2 2025 Earnings Call - Accelerating TRUVEGA Growth, Profitability Deferred

electroCore posted record Q2 revenue of $7.4M, up 20% year over year, and an 87% gross margin, but the company is explicitly shifting from conservation to aggression. Management closed the Neurometric...

• Record Q2 revenue of $7.4M, up 20% year over year and 10% sequentially.
• Gross margin strong at 87%, company modeling mid-80s margins going forward.
• electroCore closed the Neurometrics acquisition on May 1, integration completed ahead of schedule.
• +15 more takeaways